Somatostatin receptor-mediated arachidonic acid mobilization: evidence for partial agonism of synthetic peptides

被引:9
作者
Alderton, F
Fan, ZPD
Humphrey, PPA
机构
[1] Univ Cambridge, Glaxo Inst Appl Pharmacol, Cambridge CB2 1QJ, England
[2] Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England
关键词
somatostatin; angiopeptin; octreotide; arachidonic acid; sst(2) receptor; sst(5) receptor;
D O I
10.1038/sj.bjp.0703862
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Somatostatin and the stable octapeptide analogues, octreotide and angiopeptin, were examined for their ability to stimulate the release of tritium from [H-3]-arackidonic acid pre-loaded CHO-K1 cells expressing human recombinant sst(2), sst(3) or sst(5) receptors. 2 Somatostatin stimulated tritium release (pEC(50)) through the sst(2) (7.8+/-0.1) and sst(5) (7.3+/-0.2), but not the sst(3) receptor. Octreotide behaved as a full (sst(2) receptor) or partial agonist (sst(2) receptor), whereas angiopeptin behaved as a weak partial agonist at both receptor types. 3 Maximum responses to somatostatin through both receptor types were significantly reduced by pertussis toxin, whereas pEC(50) estimates were unaffected. 4 Inhibition of MEK1 or Src, but not PKA, PI 3-kinases or tyrosine kinases, by reportedly selective inhibitors reduced sst(2)-mediated responses by somatostatin, but not angiopeptin. A selective inhibitor of PKC (Ro-31-8220) reduced both somatostatin and angiopeptin responses. 5 These data provide further evidence for partial agonist activity of synthetic peptides of somatostatin. Furthermore, the somatostatin receptor signalling mechanisms which mediate arachidonic acid mobilization appear to be multiple and complex.
引用
收藏
页码:760 / 766
页数:7
相关论文
共 35 条
[1]   PHOSPHOLIPASE-C ACTIVATION AND CA2+ MOBILIZATION BY CLONED HUMAN SOMATOSTATIN RECEPTOR SUBTYPES-1-5, IN TRANSFECTED COS-7 CELLS [J].
AKBAR, M ;
OKAJIMA, F ;
TOMURA, H ;
MAJID, MA ;
YAMADA, Y ;
SEINO, S ;
KONDO, Y .
FEBS LETTERS, 1994, 348 (02) :192-196
[2]   Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis [J].
Albini, A ;
Florio, T ;
Giunciuglio, D ;
Masiello, L ;
Carlone, S ;
Corsaro, A ;
Thellung, S ;
Cai, T ;
Noonan, DM ;
Schettini, G .
FASEB JOURNAL, 1999, 13 (06) :647-655
[3]   Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus [J].
Berg, KA ;
Maayani, S ;
Goldfarb, J ;
Scaramellini, C ;
Leff, P ;
Clarke, WP .
MOLECULAR PHARMACOLOGY, 1998, 54 (01) :94-104
[4]  
BITO H, 1994, J BIOL CHEM, V269, P12722
[5]   STIMULATION OF TYROSINE PHOSPHATASE AND INHIBITION OF CELL-PROLIFERATION BY SOMATOSTATIN ANALOGS - MEDIATION BY HUMAN SOMATOSTATIN RECEPTOR SUBTYPES SSTR1 AND SSTR2 [J].
BUSCAIL, L ;
DELESQUE, N ;
ESTEVE, JP ;
SAINTLAURENT, N ;
PRATS, H ;
CLERC, P ;
ROBBERECHT, P ;
BELL, GI ;
LIEBOW, C ;
SCHALLY, AV ;
VAYSSE, N ;
SUSINI, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (06) :2315-2319
[6]   Activation of adenylate cyclase by human recombinant sst5 receptors expressed in CHO-K1 cells and involvement of Gαs proteins [J].
Carruthers, AM ;
Warner, AJ ;
Michel, AD ;
Feniuk, W ;
Humphrey, PPA .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (05) :1221-1229
[8]  
DIMARZO V, 1992, J NEUROCHEM, V59, P379
[9]   Somatostatin stimulates BKCa channels in rat pituitary tumor cells through lipoxygenase metabolites of arachidonic acid [J].
Duerson, K ;
White, RE ;
Jiang, F ;
Schonbrunn, A ;
Armstrong, DL .
NEUROPHARMACOLOGY, 1996, 35 (07) :949-961
[10]   LONG-TERM EFFECTS OF ANGIOPEPTIN TREATMENT IN CORONARY ANGIOPLASTY - REDUCTION OF CLINICAL EVENTS BUT NOT ANGIOGRAPHIC RESTENOSIS [J].
EMANUELSSON, H ;
BEATT, KJ ;
BAGGER, JP ;
BALCON, R ;
HEIKKILA, J ;
PIESSENS, J ;
SCHAEFFER, M ;
SURYAPRANATA, H ;
FOEGH, M .
CIRCULATION, 1995, 91 (06) :1689-1696